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Background
BAY 41-2272 is a new type of soluble guanylate cyclase
(sGC) stimulator developed recently. Although some ben-
eficial effects of this compound on hemodynamics in
hypertension and in heart failure have been reported,
those on cardiovascular remodeling remains unknown.
The purpose of this study is to investigate the effects of
BAY 41-2272 on cardiocyte hypertrophy and extracellular
matrix (ECM) formation in the heart of angiotensin II
(Ang II)-induced hypertensive rats.
Material and Methods
Eight-week-old male Wistar rats with hypertension
induced by subcutaneous infusion of Ang II (250 mg/kg/
min) were simultaneouslly treated orally with 10 mg/kg
BAY 41-2272 twice daily for 2 weeks. BAY 41-2272 signif-
icantly reduced systolic blood pressure during the first 10
days of the treatment group compared with Ang II -
infused group (200 ± 20 vs 154 ± 27 mmHg at day10,
mean ± S.E., p < 0.05), however blood pressure reduction
became insignificant at day14. As expected, plasma level
of cGMP of the treated group rose by 133% (p < 0.05)
compared with control. Despite the incomplete suppres-
sion of blood pressure elevation, heart/body weight and
cross-sectional size of cardiocytes were significantly
decreased by BAY 41-2272 (4.20 ± 0.34 vs 3.68 ± 0.20 mg/
g, 36.3 ± 2.7 vs 25.9 ± 3.7 µm2, p < 0.01). Ang II increased
the number of coronary adventitial fibroblasts expressing
α-smooth muscle actin, a marker for myofibroblast activa-
tion, in the left ventricle, however, BAY 41-2272 markedly
reduced it by 77% (p < 0.05). When assessed by picrosir-
ius red, levels of Ang II-induced increase in collagen dep-
osition surrounding coronary arteries and in myocardial
interstitium were significantly reduced by 26% (p < 0.01)
and 29% (p < 0.05), respectively, following the treatment.
The real time-quantitative PCR revealed that BAY 41-2272
significantly down-regulated Ang II-induced gene expres-
sions of type 1 collagen (-49%, p < 0.01), transforming
growth factor-β1 (-66%, p < 0.01) and Ang II type 1 (AT1)
receptor expression (-59%, p < 0.05), in the left ventricle.
Conclusion
BAY 41-2272 effectively attenuated cardiovascular remod-
eling in the hypertensive rat heart, suppressing expres-
sions of AT1 receptor and its down-stream ECM-related
genes. Our findings suggest that sGC stimulator BAY 41-
2272 has beneficial effects on hypertensive heart disease,
counteracting the remodeling-promoting action of Ang II.
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